>>Description of the research protocol "1534"

Protocol SAKK 41/13 Aspirin. Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial.
Phase III study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Gastro-onco
Brugmann identifier : 1534
EudraCT identifier : 2015-001482-57


Involved department : Hemato-oncology
Principal investigator : Lecomte
Sponsor : EORTC
Contact : Clinical Research Unit

>This protocol was approved by the Brugmann (CE Central) ethics committee.